Synthetic B-Cell epitopes eliciting cross-neutralizing antibodies: Strategies for future dengue vaccine

22Citations
Citations of this article
92Readers
Mendeley users who have this article in their library.

Abstract

Dengue virus (DENV) is a major public health threat worldwide. A key element in protection from dengue fever is the neutralising antibody response. Anti-dengue IgG purified from DENV-2 infected human sera showed reactivity against several peptides when evaluated by ELISA and epitope extraction techniques. A multi-step computational approach predicted six antigenic regions within the E protein of DENV-2 that concur with the 6 epitopes identified by the combined ELISA and epitope extraction approach. The selected peptides representing B-cell epitopes were attached to a known dengue T-helper epitope and evaluated for their vaccine potency. Immunization of mice revealed two novel synthetic vaccine constructs that elicited good humoral immune responses and produced cross-reactive neutralising antibodies against DENV-1, 2 and 3. The findings indicate new directions for epitope mapping and contribute towards the future development of multi-epitope based synthetic peptide vaccine.

Cite

CITATION STYLE

APA

Ramanathan, B., Poh, C. L., Kirk, K., McBride, W. J. H., Aaskov, J., & Grollo, L. (2016). Synthetic B-Cell epitopes eliciting cross-neutralizing antibodies: Strategies for future dengue vaccine. PLoS ONE, 11(5). https://doi.org/10.1371/journal.pone.0155900

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free